Objective To observe the clinical effects of telbivudine and entecavir on acute-on-chronic liver failure.Methods Fifty-seven patients with acute-on-chronic liver failure infected with viral hepatitis B were chosen and divide into 2 groups: the Telbivudine group (of 28 cases) treated with 600 mg Telbivudine /day and the Entecavir group (of 29 cases) treated with 0.5 mg Entecavir /day.The indicators for observation were liver function, prothrombin time (PT) and HBV DNA.The results of observation were taken at the 2, 4, 6, 8 and 12 week respectively after the treatment.Because the survival rate was taken into account, the results of liver function and prothrombin time (PT) was taken at the 2, 4, 6 week for comparison.Results There was a significant difference in fatality rate between the Telbivudine group (21.43%) and the Entecavir group (48.28%) .Both the negative conversion rate of HBV DNA and the time of negative conversion of the two groups showed no statistical difference.In both the groups, the prothrombin time, the cholinesterase, the serum bilirubin and the serum albumin improved with prolonging the treatment time, and significant statistical difference was observed at the 2, 4, 6 weeks after the treatment (P<0.01) , and the above indicators of the patients in the telbivudine group improved earlier than in the entecavir group.Conclusion Telbivudine could decrease the fatality rate of patients with subacute-on-chronic liver failure infected with HBV.
DownLoad: